BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics

BioCryst Pharmaceuticals, Inc. (BCRX)

Today's Latest Price: $8.80 USD

0.21 (2.44%)

Updated Jan 15 4:00pm

Add BCRX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

BCRX Stock Summary

  • Of note is the ratio of Biocryst Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 18.83% of US stocks have a lower such ratio.
  • BCRX's price/sales ratio is 28.34; that's higher than the P/S ratio of 91.87% of US stocks.
  • Revenue growth over the past 12 months for Biocryst Pharmaceuticals Inc comes in at 352.07%, a number that bests 97.98% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Biocryst Pharmaceuticals Inc, a group of peers worth examining would be XFOR, PTCT, LOGC, DRRX, and MGEN.
  • BCRX's SEC filings can be seen here. And to visit Biocryst Pharmaceuticals Inc's official web site, go to

BCRX Stock Price Chart Interactive Chart >

Price chart for BCRX

BCRX Price/Volume Stats

Current price $8.80 52-week high $8.99
Prev. close $8.59 52-week low $1.58
Day low $8.39 Volume 5,880,400
Day high $8.99 Avg. volume 4,471,240
50-day MA $6.38 Dividend yield N/A
200-day MA $4.66 Market Cap 1.55B

BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio

Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.

BCRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BCRX Latest Social Stream

Loading social stream, please wait...

View Full BCRX Social Stream

Latest BCRX News From Around the Web

Below are the latest news stories about Biocryst Pharmaceuticals Inc that investors may wish to consider to help them evaluate BCRX as an investment opportunity.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst common stock on December 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $7.45 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service wit...

Yahoo | January 7, 2021

BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m. ET. Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at BioCryst Pharmaceuticals BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the preventio...

Yahoo | January 6, 2021

Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More

Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.

Yahoo | December 23, 2020

BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall

BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).

Yahoo | December 23, 2020

2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started

If you are looking for high-growth healthcare stocks that could go even higher, check out BioCryst Pharmaceuticals (NASDAQ: BCRX) and Cryoport (NASDAQ: CYRX). On Dec. 3, the U.S. Food and Drug Administration (FDA) approved the company's lead asset, Orladeyo (berotralstat), as the first oral, once-daily pill to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years or older. The market considers this to be a major win, since BioCryst's market capitalization has swooped up from $900 million just prior to the FDA's announcement to around $1.4 billion as of Dec. 17.

Yahoo | December 23, 2020

Read More 'BCRX' Stories Here

BCRX Price Returns

1-mo 2.21%
3-mo 146.84%
6-mo 80.70%
1-year 216.55%
3-year 54.93%
5-year 25.89%
YTD 18.12%
2020 115.94%
2019 -57.25%
2018 64.36%
2017 -22.43%
2016 -38.66%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9138 seconds.